#Timelane animal hospital full#
#Timelane animal hospital trial#

#Timelane animal hospital trial#

Participation will require a total of up to 17-visits over 1 year.ДЇor more information on this study please contact: the subject pertaining to the trial of interest.

#Timelane animal hospital full#

A full screening will be performed prior to enrollment.

Pet owners must be willing to transport their dog to and from the treatment center in Columbia, MOВ for every visit abiding by specific timelines.

It is possible that this immune reaction might improve outcome by reducing recurrence and spread of the tumor. Induce an immune reaction againstВ the tumorВ cells.This trial uses the bodyвЂ™s own immune system and patient specific malignant cells to combat disease.Complete costВ of all treatments and re-rechecksВ covered by study.В Does not include initial staging or adverse side effects.Has not received chemotherapy, radiation, or any immunotherapy within 3 weeks of study participation.No secondВ malignancyВ that is not in remission.No metastatic disease at time of diagnosis.Does not have a current bacterial infection requiring systemic therapyВ and has not been treated for bacterial infection in the 7 days prior to study enrolment.Adequate renal, hepatic and hematologic parameters.Histologic or cytologic confirmedВ soft tissue sarcoma.The University of Missouri Veterinary Medical Center is enrolling patients into a clinical trial evaluating theВ safety and effectiveness for a treatment that is specificallyВ intended to treat dogs with sarcoma. Participation will require a total of up to 2 visits.Pet owner must be willing to transport their dog to and from the treatment center in Columbia, MO.Initial staging cost are ownerвЂ™s financial responsibility as well as adverse side effects.We will also evaluate t he impactВ of cancer within lymph nodesВ on survival in affected dogs and t he accuracy of CT for detection of lymph node involvement. The primary goal of this study is to determine if special stains improve detection of cancer within lymph nodescompared to standard staining.No previous chemotherapy or radiation treatment for the affected tissue.Imaging of neck with ultrasound or CT before surgery.The University of Missouri Veterinary Medical Center is enrolling patients into a clinical trial to evaluate regional lymph node metastasis in canine thyroid carcinoma. Participation will require a total of up to 10 visits overВ 2 months.ДЇor more information on this study please contact: with the subject pertaining to the trial of interest.A full screening will be performed prior to full study enrollment.Pet owners must be willing to transport their dog to and from the treatment center in Columbia, MO for every visit abiding by specific timelines.Contribute to development of an important cancer therapy.Goal of identifying maximally tolerated dose as well as pharmacokinetics and pharmacodynamics.This trial is being conducted concurrently with human trials.Complete cost of all treatments and re-rechecks covered by study, include initial staging or adverse side effects.Significant co-morbid illness, which includes, but is not limited to, renal or hepatic failure, history of congestive heart failure or clinical coagulopathy.No corticosteroids or L-asparaginase for 7 days prior to study initiation (exclusive TdCydВ and Aza-TdCВ administration required).Dogs must be off all such therapy for 2 weeks prior to study enrollment (exception L-asparaginase). No concurrent chemotherapy or radiation therapy.Lymphoma: Nodal presentation (stage 2 or greater) with at least 3 lymph nodes of в‰Ґ3cm in the longest dimension for biopsy.Solid tumors: Solid, non-sarcomatous tumor, readily accessible for biopsy, with size of в‰Ґ3cm in the longest dimension, AND a draining lymph node accessible for AND amenable to repeated aspiration (with or without image guidance).Histologically confirmed lymphoma or solid tumorВ (lymphoma may be confirmed by pre-treatment biopsy or cytology).The University of Missouri Veterinary Medical Center is enrolling patients into a clinical trial evaluating the safety and effectiveness TdCydВ and Aza-TdC, novel anticancer agents, when given to dogs with cancer.